BidaskClub upgraded shares of AC Immune (NASDAQ:ACIU) from a buy rating to a strong-buy rating in a research report released on Thursday morning.
A number of other research analysts have also weighed in on ACIU. Zacks Investment Research lowered shares of AC Immune from a buy rating to a hold rating in a research report on Tuesday, October 9th. Leerink Swann initiated coverage on shares of AC Immune in a research report on Monday, November 12th. They set an outperform rating and a $18.00 price target on the stock. Finally, UBS Group initiated coverage on shares of AC Immune in a research report on Friday, January 4th. They set a buy rating and a $16.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $15.40.
Shares of AC Immune stock traded down $0.05 during trading hours on Thursday, reaching $10.75. The company’s stock had a trading volume of 54,000 shares, compared to its average volume of 140,550. AC Immune has a one year low of $7.16 and a one year high of $17.40. The firm has a market capitalization of $708.02 million, a price-to-earnings ratio of -36.37 and a beta of 1.33.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new position in shares of AC Immune during the third quarter valued at about $107,000. Belpointe Asset Management LLC purchased a new stake in AC Immune during the third quarter worth about $400,000. Sphera Funds Management LTD. purchased a new stake in AC Immune during the third quarter worth about $4,029,000. Renaissance Technologies LLC increased its holdings in AC Immune by 131.6% during the third quarter. Renaissance Technologies LLC now owns 52,300 shares of the company’s stock worth $418,000 after buying an additional 29,720 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in AC Immune during the third quarter worth about $2,279,000. 29.06% of the stock is currently owned by institutional investors.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Read More: Yield Curve
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.